A 63-year-old with T2DM (HbA1c 65 mmol/mol despite metformin) has CKD (eGFR 52) and heart failure. Which agent offers glycaemic control and cardiorena...

Question

A 63-year-old with T2DM (HbA1c 65 mmol/mol despite metformin) has CKD (eGFR 52) and heart failure. Which agent offers glycaemic control and cardiorenal benefit?

Accepted Answer

SGLT2 inhibitor (empagliflozin)

Answer

Gliclazide

Answer

DPP-4 inhibitor (sitagliptin)

Answer

Basal insulin

Answer

Pioglitazone

ukmla MCQ (SBA): Type 2 Diabetes

A 63-year-old with T2DM (HbA1c 65 mmol/mol despite metformin) has CKD (eGFR 52) and heart failure. Which agent offers glycaemic control and cardiorenal benefit?